COMPARE · Reviewed July 29, 2026
ANIP vs LLY
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 84.2, LLY scored 72.0 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
84.2
$80.52 · $1.8B
fundamentals as of
Score gap
12.2
ANIP leads
LLY
Eli Lilly and Co
72
$1,160.50 · $1.1T
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
LLY
64
Qualityreturns · margins · balance sheet
73
100
Growthrevenue & earnings expansion
100
93
Valuevaluation vs sector peers
54
ANIP and LLY split the three pillars evenly.
Fundamentals, head-to-head
ANIP
LLY
$191mC
FCF
$11.8bA-
+37.0%A
Rev
+47.4%A
1.12C
D/E
1.60C
20.6xB+
P/E
43.8xC
0.48A
PEG
0.92B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
LLY
49% below
Price vs fair valuelower is cheaper
141% above
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
~36%/yr
+70%
1-yr DCF upside
-69%
+97%
5-yr DCF upside
-58%
+141%
10-yr DCF upside
-36%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
LLY
Why this score
- Raising its dividend
- Short track record
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. 19% off the 52-week high of $99.50. Revenue growing +37% — in hypergrowth territory. PEG 0.48 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $110.00 (implying +37% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
LLYEli Lilly and Co
Why now
Pharmaceuticals · market cap $1.1T. 7% off the 52-week high of $1249.45. Revenue growing +47% — in hypergrowth territory. PEG 0.92 — paying under fair value for the growth rate.
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 101% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Trailing P/E 44x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 15.3x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.